Stilbene AhR Agonist Derivatives With Lower Toxicity and Better Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AhR agonists like TCDD and benvitimod suffer from environmental toxicity, clinical limitations, and instability, necessitating the development of novel compounds with improved efficacy, bioavailability, and stability for treating autoimmune and inflammatory diseases.
Innovation Solution
Development of stilbene derivatives with specific substitutions and structures, such as compounds of formula (I) and (II), which exhibit strong AhR agonistic activity, stability, and low toxicity, suitable for treating autoimmune dysregulations and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TCDD is used as an AhR agonist to regulate T cell differentiation, then the balance of T cell differentiation is improved, but environmental and in vivo toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of AhR agonists by changing parameters such as introducing specific substituents (halogen atoms at positions 3 and 5, cycloalkyl groups) to create compound (I) and compound (II). These structural parameter changes result in compounds with reduced toxicity while maintaining AhR agonistic activity, as evidenced by the toxicological studies showing lower acute and chronic toxicity compared to TCDD.
2Reliability
If benvitimod is used as an AhR agonist for treating autoimmune diseases, then anti-inflammatory effect is achieved, but stability decreases due to easy oxidization in light
Solution Approach 1:
The patent addresses the stability issue by modifying the chemical structure of benvitimod through parameter changes - specifically introducing halogen substituents (fluorine or chlorine) at positions 3 and 5 of the aromatic ring, and adding cycloalkyl groups. These structural modifications create compounds with enhanced photostability and resistance to oxidization, while preserving the anti-inflammatory efficacy through maintained AhR agonistic activity.
3Reliability
If novel AhR agonists are developed to improve efficacy and bioavailability, then therapeutic effect is enhanced, but compound complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the molecule into distinct functional modules: a core stilbene structure, halogen substituents (F or Cl) at positions 3 and 5, cycloalkyl groups (cyclopentyl or cyclohexyl), and optional additional substituents. This modular segmentation allows for systematic optimization of each component's contribution to efficacy and bioavailability while maintaining overall structural clarity and synthetic feasibility.
Data Source
AI summary
The present invention relates to a stilbene derivative as an AhR activator and use thereof. The compound of formula (I), or a pharmaceutically acceptable salt, a tautomer or a stereoisomer thereof has an AhR activation effect, and can be safely used for treating a disease or a related symptom mediated by activity abnormality of AhR and related pathway targets.